McGowan Institute for Regenerative Medicine Research Featured on Cover of Prestigious Journal
The research efforts of McGowan Institute for Regenerative Medicine faculty member Kacey Marra, PhD, associate professor, Department of Surgery, and co-director of the Adipose Stem Cell Center, University of Pittsburgh, and her colleagues McGowan Institute for Regenerative Medicine faculty members Jörg Gerlach, MD, PhD, professor, Department of Surgery, University of Pittsburgh, and J. Peter Rubin, MD, chief of the UPMC Division of Plastic and Reconstructive Surgery and director of the UPMC Center for Innovation in Restorative Medicine, and co-director of the Adipose Stem Cell Center, were not only published in Tissue Engineering Part C: Methods, but were featured on the journal’s cover. Their paper is entitled “Adipogenesis of Human Adipose-Derived Stem Cells Within Three-Dimensional Hollow Fiber-Based Bioreactors” and presents the development of a coherent 3D high density fat-like tissue consisting of unilocular structure from primary adipose stem cells in vitro.
Novel Surgical Adhesive Begins Clinical Trials in the United States
Several years ago, McGowan Institute for Regenerative Medicine faculty members Eric Beckman, PhD, George M. Bevier Professor of Engineering in the University of Pittsburgh Department of Chemical and Petroleum Engineering, and Michael Buckley, MD, oral and maxillofacial surgeon, invented a novel medical adhesive technology. The new adhesive—now known as TissuGlu®—was designed to meet a market demand for a strong, safe tissue adhesive to improve the wound closure process. The product positions tissues for optimal healing while minimizing fluid accumulation. To move the University of Pittsburgh-developed technology towards clinical use, Cohera Medical, Inc. was formed, and the invention rights were licensed by the University to Cohera.
Preclinical Testing: Regenerative Medicine Stem Cell Therapy for Disabled Stroke Patients
McGowan Institute for Regenerative Medicine affiliated faculty member Michel Modo, PhD, associate professor in the Department of Radiology at the University of Pittsburgh, while at the Institute of Psychiatry, King’s College London, conducted a pivotal pre-clinical study using ReNeuron’s lead CTX neural stem cell line in a stroke model. The first clinical application for the CTX cell line is the company’s ReN001 stem cell therapy for disabled stroke patients, currently in Phase I clinical development. Study results were recently published in Stem Cells.
McGowan Institute for Regenerative Medicine affiliated faculty member Mark Roberts, MD, professor and chair in University of Pittsburgh’s Department of Health Policy and Management, is co-author of a study of new research that focuses on the composition and timing of the annual flu vaccine design. Pitt’s Swanson School of Engineering faculty members Oleg Prokopyev, PhD, an assistant professor, and Andrew Schaefer, PhD, associate professor, both in the Department of Industrial Engineering, and Osman Ozaltin, PhD, assistant professor of engineering at the University of Waterloo in Ontario, were also co-authors on the study.
Regenerative Medicine’s Potential Fountain of Youth
The published research findings of McGowan Institute for Regenerative Medicine faculty member Johnny Huard, PhD, professor in the Departments of Orthopaedic Surgery, Microbiology and Molecular Genetics, Biochemistry, Bioengineering, and Pathology, University of Pittsburgh School of Medicine, and director of the Stem Cell Research Center at Pitt and Children’s Hospital of Pittsburgh of UPMC, and affiliated faculty member Paul Robbins, PhD, professor of Molecular Genetics and Biochemistry, University of Pittsburgh School of Medicine, affirmed that mice bred to age too quickly seemed to have sipped from the fountain of youth. This occurred after the team of scientists at Pitt’s School of Medicine injected them with stem cell-like progenitor cells derived from the muscle of young, healthy animals. Instead of becoming infirm and dying early as untreated mice did, animals that got the stem/progenitor cells improved their health and lived two to three times longer than expected.
Title Generation of an Artificial Intestine for the Treatment of Short Bowel Syndrome in Children
Description The clinical condition in which the body is unable to absorb food after significant loss of the intestine is called short bowel syndrome (SBS). While its true incidence is unknown, in the United States the condition affects over 5000 children, with an estimated 15,000 older patients requiring long-term home parenteral nutrition. SBS can be caused by loss of large portions of functioning intestine – such as occurs typically as a consequence of necrotizing enterocolitis (NEC), Crohn’s disease, or as a result of a birth defect in which the intestines do not develop normally. Because food cannot be adequately absorbed by the shortened intestine, nutrients must be administered directly into the circulation through a vein. Although this approach can supply adequate calories, children who receive nutrition directly into the circulation commonly suffer from intravenous catheter infections and severe liver toxicity, with mortality around 30%. Only about one third of patients with SBS can expect to be weaned from parenteral nutrition. The majority of children with short bowel syndrome require intestinal transplantation and if toxicity from the administered nutrition is severe enough, liver transplantation, as well. While the outcome after intestinal transplantation is improving, this procedure is limited by a lack of suitable donors and complications from immunosuppressive therapy. To address the difficulty of managing short bowel syndrome in children, Hackam and March propose constructing an artificial intestine using cultured intestinal stem cells from the recipient’s intestine that can grow on a synthetic 3-dimensional bioscaffold.
Regenerative Medicine’s Potential Fountain of Youth
McGowan Institute for Regenerative Medicine faculty member Johnny Huard, PhD, professor in the Departments of Orthopaedic Surgery, Microbiology and Molecular Genetics, Biochemistry, Bioengineering, and Pathology, University of Pittsburgh School of Medicine, and director of the Stem Cell Research Center at Pitt and Children’s Hospital of Pittsburgh of UPMC, and affiliated faculty member Paul Robbins, PhD, professor of Molecular Genetics and Biochemistry, University of Pittsburgh School of Medicine, are members of a team that affirmed that mice bred to age quickly seemed to have sipped from the fountain of youth.